Trial · NCT07353294
Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC
NCT07353294, Phase 1, Enrolling by invitation, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC. Trials, record NCT07353294. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07353294
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC
- NCT number
- NCT07353294
- Status
- Enrolling by invitation
- Phases
- Phase 1
- Enrollment
- 12 participants, estimated
- Lead sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Conditions
- Bladder Urothelial Carcinoma, Lymph Node Metastasis
- Interventions
- propranolol, Tislelizumab, gemcitabine, Cisplatin
- First posted
- 2026-01-20
- Last updated
- 2026-04-22
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Dose-Limiting Toxicities (DLTs) | At the end of Cycle 1 (each cycle is 28 days) | Dose-limiting toxicities (DLTs) are defined as treatment-related adverse events occurring during the first treatment cycle that meet predefined severity criteria based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. DLTs may include grade 3 or higher non-hematologic toxicity, grade 4 hematologic toxicity, or clinically significant events leading to treatment interruption or discontinuation, as determined by the investigators. |
| Secondary | Pathological Complete Response (pCR) Rate | At the time of surgery | Pathological complete response (pCR) is defined as the absence of any residual tumor in the primary bladder lesion and in all examined regional lymph nodes following neoadjuvant therapy and surgical resection (pT0N0). The proportion of participants achieving pCR will be calculated relative to the total number of evaluable participants. |
| Secondary | Pathological Downstaging Rate | At the time of surgery | Pathological downstaging is defined as a postoperative pathological tumor stage (ypT) lower than the baseline clinical stage (cT), with downstaging to ypT2 or lower considered as treatment-induced downstaging. The proportion of evaluable participants achieving pathological downstaging will be recorded. |
| Secondary | Incidence of Treatment-Related Adverse Events | From first dose through 30 days after the last administration of study treatment | Adverse events (AEs), adverse drug reactions (ADRs), and serious adverse events (SAEs) will be collected and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Events will be summarized by frequency, severity grade, and relationship to study treatment. |
| Secondary | Progression-Free Survival (PFS) | Up to 24 months after surgery | PFS is defined as the time from study enrollment to the first documented disease progression, local or distant recurrence, or death from any cause, whichever occurs first. Participants without an event will be censored at the date of last disease assessment. |
| Secondary | Overall Survival (OS) | Up to 36 months after surgery | OS is defined as the time from study enrollment to death from any cause. Participants who remain alive at the end of follow-up will be censored at the date of last known contact. |
| Other | Proportion of exhausted CD8+ T cells among CD8+ T cells | At baseline and at time of surgery | The proportion of exhausted CD8+ T cells (identified as PD-1⁺ TIM-3⁺ CD8⁺ cells) will be quantified in tumor tissue, lymph node samples, or peripheral blood mononuclear cells obtained before and after neoadjuvant treatment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07353294
GET https://conductscience.org/api/trials/v1/NCT07353294/registered